At Diag-Nose.io, we use AI and protein signatures to help the one billion chronic respiratory patients worldwide find the right treatment faster so they can breathe better and live longer. Our RhinoMAP platform is an AI-enabled lab testing platform that enhances specialist treatment selection and monitoring capabilities with a focus is on improving patient access to Anti-Th2 biologics. Diag-Nose.io graduated from the Stanford ENT 2019 Innovation program and the Creative Destruction Lab (CDL) Computational Health 2022 program in Seattle, becoming the first Australian medtech alumni of CDL
